ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 56 Shown
  • Acute Myeloid Leukemia: Will Understanding the Biology Lead to Better Outcomes?

    Farhad Ravandi MD - 3/26/2015
    New therapeutic targets are beginning to offer improved strategies for AML treatment.
  • Ibrutinib and the Management of Patients With del(17p) CLL

    Farrukh Awan MD, MS - 3/23/2015
    How ibrutinib earned its place among first-line treatment options for patients with CLL and del(17p)
  • How I Treat My Patients With CLL Who Are Fit or Otherwise Healthy

    Jeff P. Sharman MD - 3/11/2015 1 comment / Last Comment: 3/19/2015
    Chemotherapy or novel agents for initial treatment of CLL? Learn how to best apply new molecular markers to individualize treatment for your patients who are fit or otherwise healthy.
  • Beyond R-CHOP-21: Risk-Adapted Therapy for DLBCL

    Andrew D. Zelenetz MD, PhD - 3/10/2015 1 comment / Last Comment: 3/17/2015
    An overview of investigational strategies seeking to improve outcomes with R-CHOP in DLBCL.
  • New Options for Patients With Relapsed/Refractory ALL

    Elias Jabbour MD - 2/20/2015 1 comment / Last Comment: 2/21/2015
    The use of novel targeted therapies and immunotherapies is showing promise in ALL. These agents are achieving great responses not only in pediatric patients but also in adult patients with relapsed/refractory ALL.
  • Is Immune Modulation the Future of Therapy in Follicular Lymphoma?

    Andrew D. Zelenetz MD, PhD - 2/11/2015 1 comment / Last Comment: 2/24/2015
    Insights on the utility of immunotherapy in follicular lymphoma from recent clinical trials.
  • Why I Don’t Routinely Screen Asymptomatic White Males for Prostate Cancer

    Derek Raghavan MD, PhD, FACP - 7/29/2013 11 comments / Last Comment: 8/23/2013
    Align your practice with evolving guidelines to avoid unnecessary testing of your patients with prostate cancer
  • Adding Radium-223 to Our Current Treatment Paradigm for Metastatic CRPC: My Thoughts

    David I. Quinn MD, PhD - 5/22/2013 6 comments / Last Comment: 8/29/2013
    Radium-223 extended survival in CRPC with minimal toxicity in the ALSYMPCA randomized phase III trial. So when and how should this new therapeutic agent be used in our practices?
  • CML: Why Early Response Matters

    Elias Jabbour MD - 5/20/2013 9 comments / Last Comment: 6/30/2014
    Response is the key prognostic factor for long-term outcomes in patients with CML. In this ClinicalThought post, I discuss why early response matters and offer suggestions on managing patients without optimal responses.
  • What Is the Best Approach in MDS When Hypomethylating Agents Fail?

    Jamile Shammo MD, FASCP, FACP - 5/1/2013 1 comment / Last Comment: 8/11/2013
    Currently, there is no well-defined second-line or salvage therapy for these patients. Nevertheless, there are some data to guide use of available salvage regimens.
10 of 56 Shown
Show 10 More
Loading...